Evidence map›Paper›PMID 28904691›Full record

ArticleThe Pan African medical journal2017

IL-21 Augments Rapamycin in Expansion of Alpha Fetoprotein Antigen Specific Stem-Cell-like Memory T Cells

Victor Tunje Jeza, Xiaoyi Li, Jun Chen, Zhihui Liang, Adem Onago Aggrey, Xiongwen Wu

Open access · goldAbstract read
In one paragraph

Article in The Pan African medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Victor Tunje JezaDepartment of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiaoyi LiDepartment of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jun ChenDepartment of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhihui LiangDepartment of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Adem Onago AggreyDepartment of Mathematics and Physics, Technical University of Mombasa, Kenya.
Xiongwen WuDepartment of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Huazhong University of Science and Technology · CNTechnical University of Mombasa · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlloreactive tumor specific T cells are important arsenals of the adaptive immune system in the fight against tumors. However, stem cell-like memory T cells (Tscm) provide the key to effective elimination of tumor cells. Methods for generating these T cell subsets already exist. However, they could be made more efficient. Further, they are expensive and unattainable to the resource poor laboratories. In this regard, we are hereby describing a novel in vitro allogeneic co-culture method for raising allo-restricted tumor specific Tscm cells that we developed.

methodsWe started by obtaining PBLs that screened negative for HLA-A2 molecules from healthy donors followed by co-culture with T2/AFP cells to generate AFP peptide specific tumor-reactive T cells. Controls, IL-21 and/or rapamycin were applied to samples in 24 well plates. Samples were harvested and stained with anti-human CD3, CD8, CD44, CD62L, and HLA-A2/AFP dimer followed by flow cytometry analysis. Cell viability was measured by Trypan blue exclusion assay. One Way ANOVA and independent t test were used to compare the mean differences among and between groups where P values less than 0.05 were considered significant.

resultsOur results show that rapamycin arrests the differentiation of, and expands AFP specific Tscm cells. Further, the expansion of Tscm cells is augmented in the presence of IL-21.

conclusionIL-21 and Rapamycin can be used concurrently to raise and maintain antigen specific Tscm cells

Indexed as

alpha-FetoproteinsAntigensAntineoplastic Combined Chemotherapy ProtocolsCell DifferentiationCell SurvivalCoculture TechniquesFlow CytometryHumansImmunotherapyInterleukin-21InterleukinsIn Vitro TechniquesSirolimusT-Lymphocytesalpha-FetoproteinsAntigensInterleukin-21InterleukinsSirolimusAlpha Fetoproteincancer immunotherapiesconcurrent applicationIL-21RapamycinTscm cells

Identifiers

PMID28904691
PMCPMC5567945
OpenAlexW2731693957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.